Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

January 12, 2018: By Joan McKenna

Ohr Pharmaceutical announced Jan. 5 that squalamine used in combination with Lucentis failed to meet its primary efficacy endpoint in a Phase III study in patients with wet age-related macular degeneration (AMD).

The endpoint was mean visual acuity gain at nine months. Subjects receiving topically administered squalamine with monthly Lucentis injections (n=119) achieved a mean gain of 8.33 letters from baseline, while those treated with Lucentis monotherapy (n=118) achieved 10.58 letters. There were no differences in the safety profile between the two treatment groups.

Jason Slakter, MD, chief executive officer of Ohr, expressed disappointment and said, “We are grateful to the patients and physicians who participated in the clinical trial. Based on these results, we intend to evaluate strategic alternatives to maximize shareholder value.”

In February 2017, Ohr paused enrollment in the Phase III trial at 200 following the failure of other retinal combo therapies. Ohr said the move would enable it to potentially confirm the visual acuity benefits observed in the patient population it identified as the most likely to benefit from squalamine combination therapy.

Squalamine is intended to inhibit vascular endothelial growth factor, platelet-derived growth factor, and basic fibroblast growth factor. It is based on a compound found in the tissues of the dogfish shark. The FDA granted it fast track designation for wet AMD.

Ohr acquired squalamine from by Genaera Pharma in 2009 as Genaera liquidated its assets.

In April 2017, Ohr closed a $14.2 million public offering.

In December 2016, the company closed a $7.8 million public offering.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023